Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
about
TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells.Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report.Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populationsScientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality.Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.Targeting oestrogen to kill the cancer but not the patient.The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cellsResearch resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b.Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.Integration of endocrine therapy with targeted agents.Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancerEstrogen regulation of apoptosis: how can one hormone stimulate and inhibit?Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cellsEstrogen receptor alpha inhibits senescence-like phenotype and facilitates transformation induced by oncogenic ras in human mammary epithelial cells.Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells.Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis.Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha.Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification.Oestrogen is bad for patients with breast cancer?Aromatase inhibitors: from bench to bedside and back.
P2860
Q27852459-36908BD6-1411-48BA-A87B-280DCE12A25DQ30425478-619E7F25-2DED-4D0E-AAC7-A027F63A1087Q30436904-D731C990-F92D-43EC-988A-C5AC5F601331Q33847525-A4D7F093-6F1C-4B01-89E4-82CDCDA25867Q34047152-E721091E-205F-4741-8D70-63BA93C9EFAFQ34315889-6CCDEDDE-AAF4-46B9-A4F4-844E25F049D4Q34362281-B0127AF3-7622-4CFB-A9D0-559332A705D4Q34458253-4FE6E45F-E3B0-4699-9819-80FEE64AAE0AQ34502268-771B6B98-834D-4607-B072-91349CDCC0DDQ35002418-6C099EB9-DED1-404B-835E-121C9B46E726Q35023715-28E7E823-457F-4D93-87C5-C67AA623E8A1Q35208201-36C5D2E0-86C9-430B-AE0F-3F913FAC16ACQ35663909-4E43115D-0B3A-4AD1-A38B-C6A42D35955BQ35680855-11AE5126-AF39-48B6-BA1D-3D38CC94CAA2Q35827822-2B526A6C-4310-444D-957F-515570E8E452Q36049034-3D22A1D6-71F3-45CC-ACFB-663C858E6C77Q36113804-C0BD2585-36A9-46BD-B66C-2175F8517CBCQ36464743-CA0AD4AA-F5E0-47AA-9393-9E535213755AQ36517144-136CD848-E413-409F-AA11-A28890313BC9Q36598699-7886F069-4582-44AC-BAD5-85EE2532ED88Q36684234-3AE20684-8273-49AD-ACDB-B4562296E46CQ36778032-142BF4BA-721B-4F4E-92EB-2515AF9C52E6Q36919229-B87BD0DA-2DC9-4016-BF58-E8EC564212E1Q37025060-78485377-1BFF-4C73-9C58-865BD4F7EBAFQ37039801-DA45B371-9738-4918-A54B-D193F1B1A22FQ37214089-AB79DD48-D45A-4CFC-9BC1-19DBE0DAB049Q37277121-DB8C213E-022F-492F-9289-8227D73D32E9Q37279990-2DE12425-87BB-4699-BED8-B6159D4A2183Q37346786-7C63A26E-0C09-433A-AD8F-DB534B895166Q37376013-E72B5334-F4A9-4785-978F-4FBEBD237E23Q37401741-DFC8AF93-14DB-4700-9A01-93D036E35096Q37457407-6A96580C-37CE-4961-A27A-418F2919EC80Q37626072-7EEFDA90-E975-448F-AA1D-56686D9F5A25Q37650708-27925B2F-5C9E-4527-AAE9-9445CD70C864Q38846195-D577E5E1-4394-452E-A024-0B7FB692A696Q40342717-99B1E420-DE76-4EB4-AD44-A3C9DC66203DQ40375704-521EFCA0-F569-419E-8077-7AE56140FAD3Q41635802-AEB2A62D-ABF5-4E82-84E7-D7C3CD93DA3CQ45788419-A5DE3D71-4646-429A-A356-C4A526B5CBFFQ46788411-40BC2317-DC01-4686-BDDC-B173221D3E43
P2860
Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@en
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@nl
type
label
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@en
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@nl
prefLabel
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@en
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@nl
P2093
P356
P1476
Paradoxical action of fulvestr ...... ifen-stimulated breast cancer.
@en
P2093
Clodia Osipo
Csaba Gajdos
V Craig Jordan
P304
P356
10.1093/JNCI/DJG079
P407
P577
2003-11-01T00:00:00Z